We are live on ! Find out more

Charles River Laboratories

CRL

Market cap $13.1B

273.87 USD

-4.39

1.58%

At close Updated Sep 14, 12:49 PM EDT

1 day

-1.58%

5 days

-4.11%

1 month

-2.21%

3 months

45.31%

6 months

80.21%

Year to date

35.3%

1 year

79.89%

5 years

-37.22%

10 years

239.96%

About: Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.

Employees: 19,700

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 55.6%

Neutral 44.4%

Negative 0%

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences.

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity. Reaching full operational capacity in Q3 2026, the automated suite is a major investment in advanced.

Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite

Zacks Investment Research

Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Is This the Right Time to Add CRL Stock to Your Portfolio?

Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.

Is This the Right Time to Add CRL Stock to Your Portfolio?

22 best-performing stocks of August, as the software industry continues its recovery

The energy and technology sectors did well in August, while Moderna's stock was the best performer by a wide margin.

22 best-performing stocks of August, as the software industry continues its recovery

The Motley Fool

Wall Street Is Now Backing the Clarity Act. Here's the Most Likely Scenario for What Happens Next With Crypto.

According to prediction markets, final passage of the Clarity Act is not likely to happen until mid-2027 at the earliest. If the Clarity Act stalls out in Congress, the crypto industry will need to rely on favorable rule making from the likes of the SEC, CFTC, and OCC.

Wall Street Is Now Backing the Clarity Act. Here's the Most Likely Scenario for What Happens Next With Crypto.

Zacks Investment Research

CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?

Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.

CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?

Zacks Investment Research

Charles River Gains 88.6% in a Year: What's Driving the Rally?

CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.

Charles River Gains 88.6% in a Year: What's Driving the Rally?

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC's next-generation multivalent.

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing

How an Insider CEO Is Taking a Fresh Look at Charles River

Even after 35 years and by her count 16 or 17 different jobs across every division at Charles River Laboratories, Birgit Girshick still made visiting the company's far-flung outposts one of her first priorities after taking over as CEO on May 5.

How an Insider CEO Is Taking a Fresh Look at Charles River

See News Rankings

Price charts implemented using Lightweight Charts™